Union Square Ventures

Lux Capital is a venture fund that invests in emerging science and technology ventures at the outermost edges of what is possible. We partner with bold entrepreneurs who are challenging the status of quo - and we are willing to bet on them when no-one else can or will. Our team is comprised of neuroscientists, chemists, data scientists, computational biologists, economists, electrical engineers, machine-learning hackers and philosophers. Lux Capital was founded by Peter Hebert, Robert Paull and Josh Wolfe in the year 2000 and has its headquarters in New York with an additional Silicon Valley office.

Canaan Partners is an early-stage venture capital firm investing in technology and healthcare companies in the United States.

Notable Capital is a US venture capital firm that partners with early-stage technology founders. It became the independent US-focused successor to GGV Capital in March 2024, while GGV Capital's Asian operations rebranded as Granite Asia. The firm reports more than 25 years of experience and over USD 5 billion in assets under management.

Northzone is a European early-stage venture capital fund that invests in innovative consumer and enterprise companies in Europe and the US East Coast,. We invest primarily at the Series A and B stage, but selectively pursue seed investments. We have deep, long-standing technology expertise and benefit from the fact that the majority of our investment team have previously founded companies.

Greycroft Partners is a New York based venture capital firm with a flexible, long term investment approach. We can invest at any stage of a startup's lifecycle, and have separate funds that invest at earlier stages ($100K to $5m first cheque, with follow-on rounds up to $10m) and later stage pre-IPO rounds ($10m first cheque, up to $35m total). Greycroft is flexible on ownership percentage, check size, and board seats which means we can bring together syndicates that may be impossible with the stricter requirements of other funds. We are truly long-term, and we often hold investments for over ten years. Although we have a greater number of investments in the US, we can and have invested globally, including Europe and Asia. Our portfolio companies benefit from active, hands-on assistance from the partners. Greycroft's partners work as a team, which means our CEOs have access to the collective rolodex and expertise of the entire partnership. We leverage an extensive network of media and technology connections to help you gain visibility, build strategic partnerships, and successfully exit.

Innovation Endeavors is a venture capital firm focused on visionary founders, transformational technology and emergent ecosystems for a new world. Innovation Endeavors was co-founded by Eric Schmidt (ex-CEO and Chairman of Google), who remains an anchor investor, and merged with Herzilya, an Israel-based fund, in August 2017. Innovation Endeavors has offices in Silicon Valley, Tel Aviv and New York, and focuses its investment efforts on North America, Europe and the Middle East.

Octopus Ventures is one of Europe's most active experienced venture capital firms, and has invested in more than 100 companies since its 1999 founding. Octopus Ventures invests in both enterprise and consumer-focused startups, and participates from Seed (typical investment $1m) to Series A (typical investment $4m). Our team knows what it is like on the other side of the fence. Before joining Octopus, many of the team established themselves in other industries, from consumer goods and professional services to technology and telecoms, and several launched and sold their own startups.

New Leaf Venture Partners is an early and growth-stage investor exclusively focused on healthcare technology. We invest across four sectors of healthcare technology: biopharmaceuticals, information convergence, medical devices and life science tools. In Biopharmaceuticals we invest from seed (creation) stage through to IPO and beyond. We look for large unmet medical needs, strong science, well differentiated technologies, and high-quality pre-clinical and clinical development programs. In Information Convergence (which includes healthcare IT, tools and diagnostics) we invest from early stages through to companies with revenues of $100m+. We have a similar approach in Medical Devices (where we look for important medical devices with the power to reduce costs and improve efficiencies in the healthcare system) and Life Sciences (where we look for products that accelerate the discovery process, uncover novel insights into the biology of disease and health, and personalize diagnoses and treatment).

SOSV is a venture capital manager investing in deep-tech companies from pre-seed through follow-on rounds. It also operates founder programs including HAX, SOSV SF and SOSV NY.

Correlation Ventures is a venture capital firm that specialises in co-investing with other venture firms. We use analytics from an in-house database of venture capital financings and portfolio company returns to assist our investment decisions, and rely on this data instead of intuition in our investment decisions. We provide fast access to capital, making investment decisions in under two weeks, and are very flexible on terms and investment size. Correlation Ventures only invests in private, US-headquartered companies, and we only invest where at least one venture firm co-investing in the round is also making its first investment in the company.

King River Capital is a venture capital fund based in Sydney and San Francisco, investing primarily in Australia and the United States. King River focuses on high-growth software and AI-driven technology businesses that are generating meaningful revenues

First Round Capital is a specialist very early stage (including pre-seed, seed, angel rounds) investor. As our name suggests, no idea is too early. We love rolling up our sleeves to help build from day one. First Round has deep expertise an extensive network across the startup community, and the entrepreneurs we invest in have full access to our connections and insight. More than most venture firms, we help startups with the most difficult problems they face, including hiring, fundraising and business issues. We do not invest in later stage rounds except for follow-on rounds of our portfolio companies. Although our investment tend to cluster around enterprise, consumer, hardware, fintech and healthcare, we invest in all sectors.

Bloomberg Beta is an early-stage venture firm backed by Bloomberg L.P. It invests through a seed fund focused broadly on the future of work and an opportunity fund for later-stage investments in companies it has backed.

Forum Ventures is an early-stage B2B software investor with pre-seed funds, an accelerator, and a venture studio that co-builds companies from concept stage.

ff Venture Capital (ffVC) is a venture capital firm based in New York that leads seed and Series A rounds in technology startups based in the region, broader US, and select other countries including Canada and Israel. We usually lead investments, and contribute between $500K and $750K per deal initially, and up to $5m in follow-on investments. Our team actively works with founders to develop products, target markets, and accelerate growth. With expertise and investments in artificial intelligence, cyber security, machine learning, UAVs, enterprise software, crowdfunding, data analytics and more, we seek emerging, transformative technology and technology-driven founders who create and lead companies that will influence the behavior of millions.

Courtside Venture Capital is a Detroit-headquartered fund that invests in early-stage founders that are transforming the intersection of sports, technology and media. Our team and founders are highly specialized sports and media entrepreneurs and investors, and we look to utilize our industry networks and deep domain knowledge to bring unparalleled value to our companies. Courtside VC builds long-term partnerships with management and provides ongoing strategic support across all aspects of operations.